Enanta to present Phase 2 trial data for RSV drug candidate zelicapavir at IDWeek 2026
Enanta Pharmaceuticals flagged new Phase 2 results for RSV drug candidate zelicapavir, scheduled for presentation at IDWeek 2026. Trial data indicate faster symptom resolution, fewer hospitalizations, lower viral burden versus placebo in high-risk adults. Presentation is set for Oct. 22, 2026, positioning zelicapavir a